AMGN - AMGEN Inc Stock Analysis

AMGEN Inc (AMGN) is a publicly traded company listed on the Large. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 175.08B, generates annual revenue of 37.30B, and reports net income of 7.80B. As of the latest data, the stock is trading at 324.39 USD.

From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company is highly leveraged, which may pose risks during economic downturns or periods of rising interest rates. The stock offers a moderate dividend yield (3.14%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.

Analyst recommendation stands at Hold (3.52), indicating current market sentiment. Institutional ownership is reported at 82.19%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 19.08%, trading within a 52-week range of 267.73 - 391.29.

AMGN - AMGEN Inc

324.39
Analyst Consensus
Hold 3.52
AMGN – Analyst Rating Summary
Analyst Pie Chart
  • Strong Buy: 6
  • Buy: 15
  • Hold: 20
  • Sell: 2
  • Strong Sell: 1
  • Total Analysts:  44

Last update: 2026-05-19 04:26:40
Index: DJIA, NDX, S&P 500 P/E: 22.56 EPS (ttm): 14.38 Insider Own: 0.23% Shs Outstand: 539.70M Perf Week: -1.58%
Market Cap: 175.08B Forward P/E: 13.83 EPS next Y: 23.45 Insider Trans: -4.62% Shs Float: 538.49M Perf Month: -8.70%
Income(ttm): 7.80B PEG: 3.62 EPS next Q: 5.59 Inst Own: 82.19% Short Float: 2.41% Perf Quarter: -13.12%
Revenue(ttm): 37.30B P/S: 4.69 EPS this Y: 2.50% Inst Trans: 1.89% Short Ratio: 4.88 Perf Half Y: -3.46%
Book/sh: 17.03 P/B: 19.05 EPS next Y: 4.74% ROA: 8.58% Short Interest: 12.97M Perf Year: 19.08%
Cash/sh: 22.30 P/C: 14.54 EPS next 5Y: 3.82% ROE: 101.32% 52W Range: 267.73 - 391.29 Perf YTD: -0.89%
Dividend Est.: 10.20 (3.14%) P/FCF: 20.36 EPS past 3/5Y: 5.51% 2.93% ROIC: 12.77% 52W High: 391.29 -17.10% Beta: 0.42
Dividend TTM: 9.80 (3.02%) Quick Ratio: 1.01 Sales past 3/5Y: 12.09% 7.79% Gross Margin: 71.51% 52W Low: 267.73 21.16% Perf 5Y: 29.31%
Dividend Ex-Date: May 15, 2026 Current Ratio: 1.26 EPS Y/Y TTM: 31.14% Oper. Margin: 31.75% RSI (14): 36.90 Volatility: 2.24% 2.08%
Employees: 31500 Debt/Eq: 6.24 Sales Y/Y TTM: 9.94% Profit Margin: 20.91% Recom: 2.43 Target Price: 356.59
Option/Short: Yes / Yes LT Debt/Eq: 5.65 EPS Q/Q: 4.57% Payout: 66.92% Rel Volume: 0.76 Prev Close: 326.31
Sales Surprise: 0.50% EPS Surprise: 8.04% Sales Q/Q: 6.93% Earnings: Apr 30 AMC Avg Volume: 2.66M Price: 324.39
SMA20: -3.35% SMA50: -6.53% SMA200: -0.63% Undervalued: 9.93%
Volume: 2,030,002 Change: -0.59%
Graham's revised valuation formula
Discounted cash flow (DCF) model
Margin of safety

About AMGEN Inc

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.

Copyright © 2024 - 2026 www.stocks-expert.com All Rights Reserved.